Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients

2023; Elsevier BV; Volume: 251; Linguagem: Inglês

10.1016/j.clim.2023.109321

1521-7035

Jordana Rodrigues Barbosa Fradico, Ana Carolina Campi‐Azevedo, Elaine Speziali, Lis Ribeiro do Valle Antonelli, Vanessa Peruhype-Magalhães, Izabela Maurício de Rezende, Pedro Augusto Alves, Marcelo Antônio Pascoal-Xavier, Leonardo Soares Pereira, Maria Rita Teixeira Dutra, Dario Brock Ramalho, Adriana Regina Campolina Cenachi, Ludmila de Paula, Tayrine Araújo Santos, Rodrigo Fabiano do Carmo Said, Carlos Eduardo Calzavara-Silva, Jordana Grazziela Coelho-dos-Reis, Clara Ramos de Magalhães, Lara Luíza Cerávolo Rabelo, Valéria Valim, Joaquim Pedro Brito‐de‐Sousa, Ismael Artur da Costa-Rocha, Matheus de Souza Gomes, Laurence Rodrigues do Amaral, Sheila Maria Barbosa de Lima, Gisela Freitas Trindade, Renata Tourinho Santos, Juliana Fernandes Amorim da Silva, Thomas P. Monath, A. Desirée LaBeaud, Betânia Paiva Drumond, Olindo Assis Martins‐Filho, Andréa Teixeira−Carvalho,

Viral Infections and Outbreaks Research

This study described a soluble mediator storm in acute Yellow Fever/YF infection along the kinetics timeline towards convalescent disease. The analyses of the YF Viral RNAnemia, chemokines, cytokines, and growth factors were performed in YF patients at acute/(D1-15) and convalescent/(D16-315) phases. Patients with acute YF infection displayed a trimodal viremia profile spreading along D3, D6, and D8-14. A massive storm of mediators was observed in acute YF. Higher levels of mediators were observed in YF with higher morbidity scores, patients under intensive care, and those progressing to death than in YF patients who progress to late-relapsing hepatitis/L-Hep. A unimodal peak of biomarkers around D4-6 with a progressive decrease towards D181-315 was observed in non-L-Hep patients, while a bimodal pattern with a second peak around D61-90 was associated with L-Hep. This study provided a comprehensive landscape of evidence that distinct immune responses drive pathogenesis, disease progression, and L-Hep in YF patients.